Clinical Trial Search

Primary: Percentage of Participants With a Modified sPGA-G Response at Week 16 — 19.5; 39.6 Percentage of participants — p=0.0003

Primary: Number of Participants Achieving Static Physician Global Assessment (sPGA) of Genitalia (0,1) — 6; 55 Participants — p=<0.001

Primary: Study-G: Percentage of Participants With Achievement of Static Physician Global Assessment of Genitalia (sPGA-G) of 0 or 1 at Week 16 — 13.0; 69.1 percentage of…

Primary: Efficacy as Measured by the Mean Percentage Change in the Product of Static Physician Global Assessment (sPGA) and Body Surface Area (BSA). — 53.06; 65.6 percentage of…

Primary: Absolute Change in Total Clinical Score (TCS) of Clinical Signs (Sum of Erythema, Scaling and Infiltration) at End of Treatment Compared to Baseline — -6.00; -4.96…

Primary: Change in Histology

Primary: Percentage of Subjects Preffering Clobetasol Propionate Shampoo Better Than Comparator — 28.5; 31.6; 21.8 Percentage of participants — p=0.0003

Primary: Percentage of Participants Achieving a Genital Vitiligo Noticeability Scale (VNS) of "4 - A Lot Less Noticeable" or "5 - No Longer Noticeable" at Week 48 — 27.0…

Primary: Psoriasis Severity — 4.25 units on a scale

Primary: Severity of Psoriasis — 2.68; 1.84 units on a scale

Primary: The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques. — 0 participants

Primary: Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0 or 1 — 7; 2 Participants

Primary: Investigator Global Assessment (Scalp Only) — 1.59 score on a scale

Primary: Mean Percent Change of mNAPSI (Modified Nail Area Psoriasis Severity Index) at Week 36 Compared to Baseline for All Nails. — 64.1 percentage of reduction in mNAPSI score…

Primary: The Percentage Change in Psoriasis Area and Severity Index (PASI) of the Face Last Observation Carried Forward (LOCF) at End of Treatment — -60.8; -54.2 percentage of…

Primary: Efficacy of Blue Light Therapy for Patients With Grover's Disease — 27; 6 lesion count

Primary: Proportion of Subjects Achieving Complete Clearance of All Warts (Baseline and New) at the End of Study. — 0.248; 0.294; 0.09 proportion of participants

Primary: Percentage of Participants Who Achieved Success in Physician's Global Assessment (PGA) of Disease Severity at Day 84 — 17.4; 13.6 percentage of participants

Primary: Percentage of Participants With Time to First GH Recurrence — 43; 71 Percentage of participants — p=<0.001

Primary: Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4 — -53.97; -41.01; -24.26; -17.24 percent change

Primary: Modified NAPSI Score (Nail Psoriasis Severity Index) — 6.3; 6.0 units on a scale

Primary: Cutaneous Microbiota Shannon's Alpha Diversity at Baseline — -0.05; 0.06; -0.06; 0.12 Shannon's index

Primary: Time to First Generalized Pustular Psoriasis (GPP) Flare — 37.3; NA; NA; NA weeks — p=0.002

Primary: Change in Total Clinical Score From Baseline to Day 22 — -3.6; -3.7; -4.9; -1.3 units on a scale

Primary: Change in Total Clinical Score (TCS) of the Clinical Symptoms Compared to Baseline (Day 1) — -1.60; -4.96; -3.04; -3.96 score on a scale — p=<0.001

Primary: Efficacy: Complete Clearance of Baseline External Genital and Perianal Warts at or Before Week 12 — 2; 5; 2; 10 Participants

Primary: Number of Participants With PASI-75, or a 75% Improvement From Baseline in PASI Score — 1 Participants

Primary: Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (≥) 2 Grade/Point Improvement From Baseline at Week…

Primary: 75% Improvement in Modified Palmoplantar Pustulosis Area and Severity Index (m-PPPASI) From Day 0 — 1; 4 Participants

Primary: Percentage of Participants With Psoriatic Arthritis (PsA) Based on Physical Examination, Medical History and Laboratory Results — 30.0 Percentage of participants